Signaturefd LLC Has $137,000 Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Signaturefd LLC boosted its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 16.9% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 7,583 shares of the company’s stock after acquiring an additional 1,094 shares during the quarter. Signaturefd LLC’s holdings in Teva Pharmaceutical Industries were worth $137,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Maple Rock Capital Partners Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 68.3% in the first quarter. Maple Rock Capital Partners Inc. now owns 4,363,401 shares of the company’s stock valued at $61,568,000 after buying an additional 1,770,000 shares in the last quarter. Iron Triangle Partners LP lifted its position in Teva Pharmaceutical Industries by 113.1% in the 1st quarter. Iron Triangle Partners LP now owns 2,769,864 shares of the company’s stock valued at $39,083,000 after acquiring an additional 1,469,864 shares in the last quarter. Driehaus Capital Management LLC acquired a new position in Teva Pharmaceutical Industries during the 2nd quarter valued at about $23,115,000. Davidson Kempner Capital Management LP increased its holdings in Teva Pharmaceutical Industries by 152.5% during the 2nd quarter. Davidson Kempner Capital Management LP now owns 1,765,485 shares of the company’s stock worth $28,689,000 after purchasing an additional 1,066,150 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Teva Pharmaceutical Industries by 13.4% in the second quarter. Renaissance Technologies LLC now owns 8,728,563 shares of the company’s stock worth $141,839,000 after purchasing an additional 1,031,400 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. UBS Group lifted their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Argus upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research note on Wednesday, July 10th. JPMorgan Chase & Co. increased their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Finally, Barclays lifted their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $19.67.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock opened at $17.90 on Monday. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 2.52. The business’s 50 day simple moving average is $18.01 and its 200 day simple moving average is $16.78. Teva Pharmaceutical Industries Limited has a 12 month low of $8.10 and a 12 month high of $19.08. The company has a market cap of $20.27 billion, a price-to-earnings ratio of -43.66, a PEG ratio of 1.32 and a beta of 0.88.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.58 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.03. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. The firm had revenue of $4.16 billion for the quarter, compared to analysts’ expectations of $3.99 billion. Sell-side analysts forecast that Teva Pharmaceutical Industries Limited will post 2.33 EPS for the current year.

Insiders Place Their Bets

In related news, insider Eric A. Hughes sold 24,537 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $17.25, for a total transaction of $423,263.25. Following the sale, the insider now directly owns 45,060 shares in the company, valued at approximately $777,285. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.